Bispecific antibodies in the treatment of multiple myeloma
Sep 12, 2024 · Elranatamab (Elrexfio, Pfizer, Inc) is a humanized anti-BCMA /CD3 bispecific IgG2 antibody that was approved by FDA in August 2023 for the treatment of patients with RRMM …
B-cell maturation antigen (BCMA) in multiple myeloma: rationale …
Feb 13, 2020 · Here, we review three common treatment modalities used to target BCMA in the treatment of MM: bispecific antibody constructs, antibody–drug conjugates, and chimeric …
Two to Tango: CD3/BCMA Bispecific Antibodies in Multiple …
Oct 20, 2022 · Bispecific antibodies target CD3 present on the surface of T cells and a tumor-specific antigen, in this case BCMA, present on the tumor cells, leading to anticancer activity. …
FDA approves teclistamab-cqyv for relapsed or refractory multiple ...
On October 25, 2022, the Food and Drug Administration granted accelerated approval to teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), the first bispecific B-cell maturation antigen...
Bispecific Antibodies for Multiple Myeloma: A Review of …
Various BsAbs targeting MM-specific antigens such as B cell maturation antigen (BCMA), CD38, and CD138 are currently in pre-clinical and clinical development, with promising results. In this …
BCMA-Targeted T-Cell–Engager Therapy for Autoimmune Disease
Sep 4, 2024 · In four patients with severe autoimmune disease, teclistimab, a bispecific antibody to B-cell maturation antigen and CD3, resulted in autoantibody reduction and clinical response …
A novel BCMA/CD3 bispecific T-cell engager for the treatment of ...
Dec 27, 2016 · In this manuscript, we describe the preclinical profile of a novel BCMA BiTE antibody construct (BI 836909). BI 836909 shows selective and highly potent T-cell redirected …
A BCMAxCD3 bispecific T cell–engaging antibody demonstrates …
Mar 2, 2021 · BCMAxCD3 bsAb shows similar antitumor activity compared with BCMA CAR T cells but with different in vivo kinetics. CD3-engaging bispecific antibodies (bsAbs) and …
BCMA in Multiple Myeloma—A Promising Key to Therapy
REGN5458 is a fully humanized antibody binding to BCMA on MM cells and to the CD3 on immune T cells, inducing T cell death , while cytokines release from activated T cells can be …
BCMA/CD3 Bispecific Antibodies for Multiple Myeloma (MM)
Apr 13, 2023 · BCMA/CD3 bispecific antibodies have dual antigenic specificity and promote intercellular interactions between a patient's own T cells and malignant cells that express …